Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00739596 · ClinicalTrials.gov registry record · Phase 4
Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 332
- Enrollment target
NCT00739596 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 332 participants.
The verdict
NCT00739596, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 332 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
Interventions
- DRUG Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks
- DRUG Amlodipine: 8 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00739596
The ClinicalTrials.gov registry entry for NCT00739596 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks is the first listed.
NCT00739596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00739596 about?
NCT00739596 is a clinical study titled "Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans". The purpose of the study is to evaluate the efficacy and safety of a fixed dose combination of aliskiren HCTZ versus amlodipine in African American patients with Stage 2 hypertension.
What is the current status of trial NCT00739596?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 332 participants. The study started on 2008-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00739596?
The interventions under investigation include: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks (DRUG), Amlodipine: 8 weeks (DRUG).
Who is sponsoring clinical trial NCT00739596?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.